10X Genomics Selects Kapa Biosystems as a Reagents Supplier for the GemCode Platform
News Jul 22, 2015
The GemCode Platform is a unique molecular barcoding and analysis platform that consists of instrumentation, reagents and software to generate a new data type: Linked-Reads, which deliver long range information, including haplotype phasing, structural variation, and other critical genomic information from DNA inputs as low as 1ng. Kapa Biosystems uses a proprietary directed evolution technology platform to engineer enzymes for the specific performance and functional requirements of next-generation sequencing (NGS) sample preparation. The GemCode Platform incorporates both the KAPA Hyper Prep Kit and KAPA HiFi DNA Polymerase in the library construction process to enable high-efficiency adapter ligation and low-bias library amplification.
“One of the most powerful attributes of the GemCode Platform is that it integrates with the large installed base of existing short read sequencers to generate genomic data that preserve long range information,” said Kevin Ness, CTO of 10X Genomics. “It was a straightforward decision to include Kapa Biosystems in the GemCode Platform based on the positive performance experienced by existing sequencing customers along with our own internal evaluation.”
“Kapa is excited to be working with 10X Genomics and recognizes the value of using Linked-Reads for determining structural variation and haplotype information, which is not possible with current short read sequencers,” said John Foskett, CTO of Kapa Biosystems. “Our high-efficiency library preparation reagents are designed to meet the performance requirements of demanding new applications. These products are an ideal fit for the GemCode Platform.”
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.